keyword
MENU ▼
Read by QxMD icon Read
search

Chemotherapy-induced nausea and vomiting

keyword
https://www.readbyqxmd.com/read/29234451/moxibustion-for-chemotherapy-induced-nausea-and-vomiting-a-systematic-review-and-meta-analysis
#1
REVIEW
Ziling Huang, Zongshi Qin, Qin Yao, Yuanxuan Wang, Zhishun Liu
Nausea and vomiting are distressing symptoms for patients receiving chemotherapy. Moxibustion, which involves the use of burning moxa to generate heat and stimulate acupoints, has been reported to potentially ameliorate chemotherapy-induced side effects, particularly nausea and vomiting. This systematic review evaluated current evidence on the effectiveness of moxibustion against chemotherapy-induced nausea and vomiting (CINV). We searched eight online databases and two trial registries for relevant trials...
2017: Evidence-based Complementary and Alternative Medicine: ECAM
https://www.readbyqxmd.com/read/29231783/dexamethasone-exacerbates-cytotoxic-chemotherapy-induced-lethargy-and-weight-loss-in-female-tumor-free-mice
#2
John Wong, Lisa T Tran, Kaari A Lynch, Lisa J Wood
Cytotoxic chemotherapy can induce a systemic inflammatory response which has been proposed to be an underlying mechanism of cancer treatment related fatigue. Dexamethasone, a synthetic glucocorticoid that has potent anti-inflammatory effects, is incorporated into chemotherapy regimens to prevent chemotherapy-induced nausea and vomiting (CINV). The purpose of this study was to determine whether by suppressing cytotoxic chemotherapy-induced inflammation, dexamethasone could ameliorate chemotherapy induced fatigue/lethargy in tumor free mice...
December 12, 2017: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/29231584/-electrothermal-acupuncture-in-the-prevention-and-treatment-of-chemotherapy-induced-nausea-and-vomiting-a-randomized-controlled-trial
#3
Dianrong Lu, Dianxiang Lu, Dapeng Bai, Shengqi He, Fang Wang, Yin Gao, Yanlin Du, Ningjun Wang, Zhenglong Jiang, Zemin Wang, Shijie Zhu
OBJECTIVE: To observe the effectiveness and safety of electrothermal acupuncture in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV) in the cancerous patients of phlegm-stasis interaction in cisplatin-containing chemotherapy. METHODS: Sixty cases of phlegm-stasis interaction in cisplatin-containing chemotherapy were randomized into a trial group and a control group, 30 cases in each one. In the control group, the intravenous drip of granisetron hydrochloride injection was adopted, 3 mg before and after cisplatin-containing chemotherapy 30 min, continuously for 3 days...
April 12, 2017: Zhongguo Zhen Jiu, Chinese Acupuncture & Moxibustion
https://www.readbyqxmd.com/read/29228720/gastric-myoelectric-activity-during-cisplatin-induced-acute-and-delayed-emesis-reveals-a-temporal-impairment-of-slow-waves-in-ferrets-effects-not-reversed-by-the-glp-1-receptor-antagonist-exendin-9-39
#4
Zengbing Lu, Man P Ngan, Ge Lin, David T W Yew, Xiaodan Fan, Paul L R Andrews, John A Rudd
Preclinical studies show that the glucagon-like peptide-1 (GLP-1) receptor antagonist, exendin (9-39), can reduce acute emesis induced by cisplatin. In the present study, we investigate the effect of exendin (9-39) (100 nmol/24 h, i.c.v), on cisplatin (5 mg/kg, i.p.)-induced acute and delayed emesis and changes indicative of 'nausea' in ferrets. Cisplatin induced 37.2 ± 2.3 and 59.0 ± 7.7 retches + vomits during the 0-24 (acute) and 24-72 h (delayed) periods, respectively. Cisplatin also increased (P<0...
November 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29203965/the-preventive-effect-of-the-impaired-liver-function-for-antiemetic-therapy-against-chemotherapy-induced-nausea-and-vomiting-in-hepatocellular-carcinoma-patients
#5
Tomohiro Nishikawa, Akira Asai, Norio Okamoto, Hidetaka Yasuoka, Ken Nakamura, Keisuke Yokohama, Hideko Ohama, Yusuke Tsuchimoto, Shinya Fukunishi, Yasuhiro Tsuda, Kazuhiro Yamamoto, Kazuhide Higuchi
Transarterial chemoembolization and hepatic arterial infusion chemotherapy are recommended for the treatment in patients with intermediate stage of hepatocellular carcinoma. Impaired liver function was sometime observed in patients with hepatocellular carcinoma after transarterial chemoembolization or hepatic arterial infusion chemotherapy. However, what kinds of factors deeply influence in impaired liver function are not clear. A retrospective study was performed to evaluate the risk factors of impaired liver function in cisplatin-naïve patients treated with these therapies using cisplatin...
November 2017: Journal of Clinical Biochemistry and Nutrition
https://www.readbyqxmd.com/read/29200685/a-study-on-utilization-and-evaluation-of-antiemetics-in-chemotherapy-induced-nausea-and-vomiting
#6
Gayathri Baburaj, Ansha Mariya Abraham, Lija George, Vijith Shetty, Rovin M Thempalangad, K S Rajesh, K C Bharath Raj
Purpose: Chemotherapy-induced nausea and vomiting (CINV) are the major adverse effects of cancer chemotherapy. The objectives of this study are to evaluate the utilization of antiemetics in CINV and to assess the emetogenicity of chemotherapy and to investigate the incidence of acute and delayed CINV. Methods: A prospective observational study was carried out in patients undergoing chemotherapy. A suitable data collection form was designed to collect data regarding patient's demographics, cancer type, chemotherapy regimen, antiemetic prescribed, and incidence of CINV according to the standard methods utilizing morrow assessment of nausea and emesis form...
July 2017: Indian Journal of Medical and Paediatric Oncology
https://www.readbyqxmd.com/read/29193507/incidence-of-antiemetic-induced-akathisia-in-patients-at-a-comprehensive-cancer-center
#7
A Rashid, W Baile, T Olubajo, R De La Garza
INTRODUCTION: Akathisia is a common and severely disabling medication-induced movement disorder. The condition is often missed, and patients suffer for a long time until diagnosed and managed properly. It is important to bring awareness to the clinicians for early detection and management of akathisia. METHODS: We reviewed four years record of patients seen at a comprehensive cancer center for anxiety and restlessness. Patients diagnosed with akathisia and the medications causing akathisia were identified...
November 28, 2017: Psycho-oncology
https://www.readbyqxmd.com/read/29192505/us-oncology-wide-incidence-duration-costs-and-deaths-from-chemoradiation-mucositis-and-antimucositis-therapy-benefits
#8
Ricky W McCullough
Approximate oncology-wide incidence, duration, costs and deaths associated with mucositis and identify health economic benefits of antimucositis therapies. Review the literature relevant to the clinical experience of mucositis by pathophysiology, incidence, duration, costs and deaths. Use US insurance actuarial and epidemiology on cancer to generalize an oncology-wide impact of toxic mucositis. Toxic mucositis causes oropharyngoesophageal ulcerations, chemo-induced nausea, vomiting and diarrhea. Acutely, it lasts 102 days/six cycles of chemotherapy, 60 days in human stem-cell transplantation patients and 70-84 days in head and neck cancer patients at annual costs of US$13...
December 1, 2017: Future Oncology
https://www.readbyqxmd.com/read/29187483/palonosetron-prevents-highly-emetogenic-chemotherapy-induced-nausea-and-vomiting-in-oral-cancer-patients
#9
Shinya Sento, Naoya Kitamura, Tetsuya Yamamoto, Koichi Nakashiro, Hiroyuki Hamakawa, Soichiro Ibaragi, Akira Sasaki, Natsumi Takamaru, Yoji Miyamoto, Isamu Kodani, Kazuo Ryoke, Katsuaki Mishima, Yoshiya Ueyama
BACKGROUND/AIM: To evaluate the efficacy of palonosetron in preventing acute and delayed nausea and vomiting in patients receiving highly emetogenic chemotherapy (HEC) in oral cancer patients. PATIENTS AND METHODS: Oral cancer patients receiving HEC were enrolled; among the 40 patients, 87 courses of chemotherapy were administered. On day 1, 0.75 mg palonosetron was intravenously administrated just before chemotherapy. RESULTS: The primary endpoint was the proportion of patients with a complete response (CR) and the secondary endpoint was the proportion of patients with complete control (CC) during the acute and delayed phase...
December 2017: Anticancer Research
https://www.readbyqxmd.com/read/29187462/control-of-nausea-based-on-risk-analysis-in-patients-with-esophageal-and-gastric-cancer-who-received-cisplatin-based-chemotherapy
#10
Hironori Fujii, Hirotoshi Iihara, Noriko Kajikawa, Ryo Kobayashi, Akio Suzuki, Yoshihiro Tanaka, Kazuya Yamaguchi, Kazuhiro Yoshida, Yoshinori Itoh
BACKGROUND: Cisplatin is commonly used for esophageal and gastric cancer, but has a high emetic risk. Although the control of vomiting is favorable, nausea is still poorly controlled in patients receiving cisplatin-based regimens. The present study was designed to determine the risks for cisplatin-induced nausea. The effect of olanzapine, an antipsychotic drug, as an antiemetic for patients with risk of poor control of nausea was subsequently examined. PATIENTS AND METHODS: The prevalence of antiemetic medication and the control of nausea and vomiting were retrospectively examined in patients with esophageal or gastric cancer receiving the first cycle of cisplatin-based chemotherapy...
December 2017: Anticancer Research
https://www.readbyqxmd.com/read/29177570/genetic-risk-factors-for-chemotherapy-induced-nausea-and-vomiting-in-patients-with-cancer-receiving-cisplatin-based-chemotherapy
#11
Mari Yokoi, Daiki Tsuji, Kenichi Suzuki, Yohei Kawasaki, Masahiko Nakao, Hideaki Ayuhara, Yuuki Kogure, Kazuhiko Shibata, Toshinobu Hayashi, Keita Hirai, Kazuyuki Inoue, Toshihiro Hama, Koji Takeda, Makoto Nishio, Kunihiko Itoh
PURPOSE: Younger age and female sex have already been well-known risk factors for chemotherapy-induced nausea and vomiting (CINV), and 30-50% of cancer patients still suffer from CINV. Genetic polymorphisms are suggested to influence antiemetic treatment response. METHODS: This study included a subset of patients previously enrolled in a randomised controlled trial; 156 patients were evaluated. This study aimed to evaluate the role of pharmacogenomic polymorphisms relevant to antiemetic response in patients with cancer receiving cisplatin-based chemotherapy...
November 24, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29168289/cannabinoids-for-nausea-and-vomiting-related-to-chemotherapy-overview-of-systematic-reviews
#12
REVIEW
Victor Schussel, Lucas Kenzo, Andreia Santos, Júlia Bueno, Ellen Yoshimura, Carolina de Oliveira Cruz Latorraca, Daniela Vianna Pachito, Rachel Riera
Nausea and vomiting are common and distressing adverse events of chemotherapy. This review focuses on the findings and quality of systematic reviews (SRs) of cannabinoids for chemotherapy-induced nausea and vomiting (CINV). Review of SRs, a systematic literature search, was conducted in several electronic databases and included SRs evaluating cannabinoids for CINV in cancer patients. Methodological quality and quality of reporting were evaluated by AMSTAR and PRISMA, respectively. Initial search retrieved 2,206 records, and 5 SRs were included...
November 23, 2017: Phytotherapy Research: PTR
https://www.readbyqxmd.com/read/29147855/phase-ii-study-of-palonosetron-aprepitant-and-dexamethasone-to-prevent-nausea-and-vomiting-induced-by-multiple-day-emetogenic-chemotherapy
#13
Takeshi Ioroi, Junya Furukawa, Manabu Kume, Sachi Hirata, Yuko Utsubo, Naomi Mizuta, Hideaki Miyake, Masato Fujisawa, Midori Hirai
PURPOSE: This study aimed to determine the antiemetic efficacy and safety of palonosetron, aprepitant and dexamethasone in patients with testicular germ cell tumours (TGCTs) receiving 5-day cisplatin-based combination chemotherapy. METHODS: In this open-label, single-arm, single-centre study, the antiemetic therapy consisted of palonosetron 0.75 mg on day 1, aprepitant 125 mg on day 1 and 80 mg on days 2-7 and dexamethasone 6.6 mg on days 1-7. The primary endpoint was complete response (CR; no vomiting/retching or rescue medication) in the overall period (0-240 h), and secondary endpoints included complete protection (CP; defined as CR and no more than mild nausea) and total control (TC; defined as CR and no nausea)...
November 16, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29144178/influence-of-a-dosing-time-on-toxicities-induced-by-docetaxel-cisplatin-and-5-fluorouracil-in-patients-with-oral-squamous-cell-carcinoma-a-cross-over-pilot-study
#14
Yoshiyuki Tsuchiya, Kentaro Ushijima, Tadahide Noguchi, Naruo Okada, Jun-Ichi Hayasaka, Yoshinori Jinbu, Hitoshi Ando, Yoshiyuki Mori, Mikio Kusama, Akio Fujimura
Docetaxel, cisplatin plus fluorouracil (DCF) regimen is a useful chemotherapy, but is sometimes withdrawn due to severe adverse effects (AE). In this study, we examined whether the chronotherapy of DCF regimen could reduce the drugs-induced toxicities in clinical practice. Patients with oral squamous cell carcinoma were enrolled. Chemotherapy started at 10:30 (Morning-dosing) or 18:30 (Evening-dosing) for 5 days by a cross-over design. AE were assessed for 14 days after an initiation of each dosing. The grades of nausea, vomiting and neutropenia were smaller during Evening-dosing than during Morning-dosing...
November 16, 2017: Chronobiology International
https://www.readbyqxmd.com/read/29130344/neurokinin-1-receptor-antagonists-in-the-prevention-of-chemotherapy-induced-nausea-and-vomiting-focus-on-fosaprepitant
#15
Bernardo L Rapoport, Karin Jordan, Cindy Weinstein
Chemotherapy-induced nausea and vomiting (CINV) remains a challenge in cancer care. Improved understanding of CINV pathophysiology has triggered the development of new antiemetic therapeutic options, such as selective neurokinin-1 (NK1) receptor antagonists (RAs), which effectively prevent CINV when added to a standard antiemetic regimen (serotonin-3 RA and dexamethasone). Aprepitant and its water-soluble prodrug, fosaprepitant dimeglumine, are the most widely used NK1 RAs, with extensive clinical use worldwide...
November 13, 2017: Future Oncology
https://www.readbyqxmd.com/read/29123357/complementary-therapies-for-symptom-management-in-cancer-patients
#16
Aanchal Satija, Sushma Bhatnagar
Cancer patients are often poly-symptomatic which distressingly affects their quality of lives (QOLs). Alhough, conventional management provides adequate symptom control, yet is coupled with some limitations. Complementary therapies (CTs) have shown beneficial effects in cancer patients for symptomatic relief. The aim of this article is to provide evidence-based review of commonly used CTs for symptom management in cancer care. Hypnosis has promising evidence to be used for managing symptoms such as pain, chemotherapy-induced nausea/vomiting, distress, fatigue, and hot flashes...
October 2017: Indian Journal of Palliative Care
https://www.readbyqxmd.com/read/29115898/augmented-reversal-of-cisplatin-induced-delayed-gastric-emptying-by-amla-emblica-officinalis-fruit-extract-in-sprague-dawley-rats
#17
Asad Ahmad, Mohammad Khushtar, Ranjan Kumar, Badruddeen, Ambreena Riyaz, Mohammad Irfan Khan, Azizur Rahman
Despite the availability of effective antiemetics, control of acute and delayed chemotherapy-induced nausea and vomiting (CINV) is often suboptimal and there is need of an inexpensive and safer alternative. Thus, this study was designed to evaluate the effect of Emblica officinalis Gaertn (Euphorbiaceae) fruit extract (EEEO) on cisplatin-induced delayed gastric emptying in Sprague-Dawley rats so that Emblica officinalis can be clarified for its application in CINV as a potential candidate. Groups I, II, III, IV, and V rats were pretreated orally with 1% carboxymethyl cellulose (CMC, 1 mL/kg), 1% CMC (1 mL/kg), EEEO (250 mg/kg), EEEO (500 mg/kg), and ondansetron (3 mg/kg), respectively, for 5 consecutive days...
November 8, 2017: Journal of Dietary Supplements
https://www.readbyqxmd.com/read/29112587/incidence-of-infusion-site-reactions-in-peripheral-fosaprepitant-infusions
#18
Sarah C Gonçalves, Solange M Sanches, Camila T Bueno, Diana L Villela de Castro, Aline Damascena, Giseli R C Santos
Fosaprepitant is administered intravenously to treat chemotherapy-induced nausea and vomiting. To verify the incidence of infusion site reactions and the relationship among risk factors, a quantitative retrospective cohort study was undertaken. The study included patients seen between October 2013 and February 2014. Fifty-seven patients were included in the study, and there were 105 infusions among them. Infusion site reactions were identified in 42 (40%) cases. Risk factors identified by the study included age (P < ...
November 2017: Journal of Infusion Nursing: the Official Publication of the Infusion Nurses Society
https://www.readbyqxmd.com/read/29094451/chemotherapy-induced-pica-in-rats-reduced-by-electroacupuncture
#19
Shiying Li, Yong Lei, Jiande D Z Chen
OBJECTIVES: Acupuncture or electroacupuncture (EA) has been applied for treating chemotherapy-induced emesis with limited success. The aims of this study were to investigate the anti-emetic effect of EA and to explore underlying anti-emetic mechanisms. MATERIALS AND METHODS: Rats were chronically implanted with a pair of stainless steel leads at acupoint pericardium 6 (PC6). Effects of EA with different parameters on cisplatin-induced nausea were assessed by pica (intake of kaolin, a surrogate of nausea in species without vomiting reflex)...
November 1, 2017: Neuromodulation: Journal of the International Neuromodulation Society
https://www.readbyqxmd.com/read/29092012/a-randomized-phase-3-study-evaluating-the-efficacy-of-single-dose-nepa-a-fixed-antiemetic-combination-of-netupitant-and-palonosetron-versus-an-aprepitant-regimen-for-prevention-of-chemotherapy-induced-nausea-and-vomiting-cinv-in-patients-receiving-highly-emetogenic
#20
L Zhang, S Lu, J Feng, A Dechaphunkul, J Chang, D Wang, S Chessari, C Lanzarotti, K Jordan, M Aapro
Background: Co-administration of multiple antiemetics that inhibit several molecular pathways involved in emesis is required to optimize CINV control in patients receiving highly emetogenic chemotherapy (HEC). NEPA, a fixed combination of a highly selective NK1 receptor antagonist (RA), netupitant (300 mg), and the pharmacologically distinct 5-HT3RA, palonosetron (PALO 0.50 mg), has shown superior CINV prevention compared to PALO in cisplatin and anthracycline/cyclophosphamide-based settings...
October 28, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
keyword
keyword
98586
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"